Show simple item record

dc.contributor.authorKortüm, Benedikten_US
dc.contributor.authorCampregher, Christophen_US
dc.contributor.authorLang, Michaelaen_US
dc.contributor.authorKhare, Vineetaen_US
dc.contributor.authorPinter, Matthiasen_US
dc.contributor.authorEvstatiev, Raykoen_US
dc.contributor.authorSchmid, Geralden_US
dc.contributor.authorMittlböck, Martinaen_US
dc.contributor.authorScharl, Theresaen_US
dc.contributor.authorKucherlapati, Melanie Hen_US
dc.contributor.authorEdelmann, Winfrieden_US
dc.contributor.authorGasche, Christophen_US
dc.date.accessioned2016-01-04T19:23:21Z
dc.date.issued2015en_US
dc.identifier.citationKortüm, B., C. Campregher, M. Lang, V. Khare, M. Pinter, R. Evstatiev, G. Schmid, et al. 2015. “Mesalazine and thymoquinone attenuate intestinal tumour development in Msh2loxP/loxP Villin-Cre mice.” Gut 64 (12): 1905-1912. doi:10.1136/gutjnl-2014-307663. http://dx.doi.org/10.1136/gutjnl-2014-307663.en
dc.identifier.issn0017-5749en
dc.identifier.urihttp://nrs.harvard.edu/urn-3:HUL.InstRepos:23993523
dc.description.abstractObjective: Lynch syndrome is caused by germline mutations in DNA mismatch repair genes leading to microsatellite instability (MSI) and colorectal cancer. Mesalazine, commonly used for the treatment of UC, reduces MSI in vitro. Here, we tested natural compounds for such activity and applied mesalazine and thymoquinone in a Msh2loxP/loxP Villin-Cre mouse model for Lynch syndrome. Design: Flow cytometry was used for quantitation of mutation rates at a CA13 microsatellite in human colon cancer (HCT116) cells that had been stably transfected with pIREShyg2-enhanced green fluorescent protein/CA13, a reporter for frameshift mutations. Mice were treated for 43 weeks with mesalazine, thymoquinone or control chow. Intestines were analysed for tumour incidence, tumour multiplicity and size. MSI testing was performed from microdissected normal intestinal or tumour tissue, compared with mouse tails and quantified by the number of mutations per marker (NMPM). Results: Besides mesalazine, thymoquinone significantly improved replication fidelity at 1.25 and 2.5 µM in HCT116 cells. In Msh2loxP/loxP Villin-Cre mice, tumour incidence was reduced by mesalazine from 94% to 69% (p=0.04) and to 56% (p=0.003) by thymoquinone. The mean number of tumours was reduced from 3.1 to 1.4 by mesalazine (p=0.004) and to 1.1 by thymoquinone (p<0.001). Interestingly, MSI was reduced in normal intestinal tissue from 1.5 to 1.2 NMPM (p=0.006) and to 1.1 NMPM (p=0.01) by mesalazine and thymoquinone, respectively. Thymoquinone, but not mesalazine, reduced MSI in tumours. Conclusions: Mesalazine and thymoquinone reduce tumour incidence and multiplicity in Msh2loxP/loxP Villin-Cre mice by reduction of MSI independent of a functional mismatch repair system. Both substances are candidate compounds for chemoprevention in Lynch syndrome mutation carriers.en
dc.language.isoen_USen
dc.publisherBMJ Publishing Groupen
dc.relation.isversionofdoi:10.1136/gutjnl-2014-307663en
dc.relation.hasversionhttp://www.ncbi.nlm.nih.gov/pmc/articles/PMC4680183/pdf/en
dash.licenseLAAen_US
dc.titleMesalazine and thymoquinone attenuate intestinal tumour development in Msh2loxP/loxP Villin-Cre miceen
dc.typeJournal Articleen_US
dc.description.versionVersion of Recorden
dc.relation.journalGuten
dash.depositing.authorKucherlapati, Melanie Hen_US
dc.date.available2016-01-04T19:23:21Z
dc.identifier.doi10.1136/gutjnl-2014-307663*
dash.authorsorderedfalse
dash.contributor.affiliatedKucherlapati, Melanie


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record